Patents by Inventor Scott E. Lazerwith

Scott E. Lazerwith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZASPIRO WRN INHIBITORS
    Publication number: 20250230168
    Abstract: Inhibitors of Werner syndrome helicase are provided, including compounds of Formulas J, I, II, III, IIIa, IIIa-1, and IIIa-2, pharmaceutical compositions thereof, and methods of treating cancer.
    Type: Application
    Filed: December 20, 2024
    Publication date: July 17, 2025
    Inventors: Jason E. ANESINI, Peter A. BLOMGREN, Gediminas J. BRIZGYS, Gregory F. CHIN, Wilian Augusto CORTOPASSI COELHO, Raheel FONDEKAR, Cooper S. JAMIESON, Kerry E. JONES, Andrew V. KELLEGHAN, Scott E. LAZERWITH, Joshua L. MARTIN, Luisruben P. MARTINEZ, Jonathan William MEDLEY, Michael R. MISH, Michael L. MITCHELL, David E. MORTENSON, Sierra C. NGUYEN, Michael S. SANGI, Adam J. SCHRIER, Thomas P. STRATTON, Doris T. TANG, Chandrasekar VENKATARAMANI, William J. WATKINS
  • MCL-1 INHIBITORS
    Publication number: 20250154116
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: October 17, 2024
    Publication date: May 15, 2025
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20250136621
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: December 23, 2024
    Publication date: May 1, 2025
    Inventors: Chaodi Dai, Juan A. Guerrero, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Thomas C.J. Mies, Hyung-Jung Pyun, Hayato Shiotsu, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20250109147
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 6, 2024
    Publication date: April 3, 2025
    Inventors: Chaodi Dai, Juan A. Guerrero, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Thomas C.J. Mies, Hyung-Jung Pyun, Hayato Shiotsu, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • KRAS G12D MODULATING COMPOUNDS
    Publication number: 20250101042
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 5, 2024
    Publication date: March 27, 2025
    Inventors: Wilian Augusto Cortopassi Coelho, Chaodi Dai, Juan A. Guerrero, Hongyan Guo, Darryl Kato, Scott E. Lazerwith, Jonathan William Medley, Hyung-Jung Pyun, Maoqun Tian, William J. Watkins, Jennifer R. Zhang
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20250049780
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: July 12, 2024
    Publication date: February 13, 2025
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20250042915
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: June 14, 2024
    Publication date: February 6, 2025
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • KRAS MODULATING COMPOUNDS
    Publication number: 20250042922
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 27, 2024
    Publication date: February 6, 2025
    Inventors: Chaodi Dai, Julie Farand, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Jason R. Hudlicky, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, Paulo A. Machicao Tello, James B.C. Mack, Erik P. McAuley, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Thomas P. Stratton, Maoqun Tian, Jeremy R. Tuck, William J. Watkins, Jie Xu, Jennifer R. Zhang
  • Phospholipid compounds and uses thereof
    Patent number: 12208110
    Abstract: The present disclosure relates to compounds of Formula I, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for treatment of viral infections, for example for treatment of paramyxoviridae, pneumoviridae, picornaviridae, flaviviridae, filoviridae, arenaviridae, orthomyxovirus, and coronaviridae infections.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: January 28, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • 6-SUBSTITUTED INDOLE COMPOUNDS
    Publication number: 20250002471
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: December 21, 2021
    Publication date: January 2, 2025
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Scott E. Lazerwith, Daniel G. Shore
  • MCL-1 inhibitors
    Patent number: 12162844
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: December 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • Substituted pyrrolizine compounds and uses thereof
    Patent number: 12161625
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: December 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • KRAS Modulating Compounds
    Publication number: 20240383922
    Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 10, 2024
    Publication date: November 21, 2024
    Inventors: Wilian Augusto Cortopassi Coelho, Chaodi Dai, Katherine De La Fuente, Julie Farand, Juan A. Guerrero, Tezcan Guney, Hongyan Guo, Safaa S. Jamshed, Darryl Kato, Irene N. Kiburu, Scott E. Lazerwith, James B.C. Mack, Joshua L. Martin, Jessica L. McKinley, Jonathan William Medley, Hyung-Jung Pyun, Thomas P. Stratton, Rhiannon Thomas-Tran, Maoqun Tian, Vickie H. Tsui, William J. Watkins, Jie Xu, Adam D. Zajdlik, Jennifer R. Zhang
  • Capsid inhibitors for the treatment of HIV
    Patent number: 12077537
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 3, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Thienopyrrole compounds
    Patent number: 12070455
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: August 27, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240239807
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: August 4, 2023
    Publication date: July 18, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • Phospholipid compounds and uses thereof
    Patent number: 12030904
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 14, 2023
    Date of Patent: July 9, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20240217990
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: February 8, 2022
    Publication date: July 4, 2024
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Julian A. Codelli, Lan Jiang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Scott D. Schroeder, Daniel G. Shore
  • Phospholipid compounds and uses thereof
    Patent number: 11963967
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240116946
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 11, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen